ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1972

Enhancing Patient Safety: Improving Contraceptive Counseling for Patients on Teratogenic Medications in the Rheumatology Clinic

Abimbola Fadairo-Azinge1, jobelle Romulo2, Daniella Flores3, jose Giron2, Joshua Ng4, Sarah Patterson5, Jinoos Yazdany6 and Andrew Gross6, 1UCSF, San Francisco, 2University of California San Francisco, San Francisco, 3University of California San Francisco, San Francisco, CA, 4University of California San Francisco, SAN-FRANCISCO, CA, 5University of California, San Francisco, Pacifica, CA, 6UCSF, San Francisco, CA

Meeting: ACR Convergence 2025

Keywords: Outcome measures, quality of care, Women's health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1972–1989) Measures & Measurement of Healthcare Quality Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: The American College of Rheumatology (ACR) recommends contraceptive counseling for reproductive-age women with rheumatic and musculoskeletal diseases (RMDs), especially those on teratogenic medications. These medications are associated with major birth defects, making it critical to ensure effective contraception counseling for these patients At the time of the pre-intervention assessment, among 109 patients with rheumatologist diagnoses seen in the UCSF rheumatology clinic who were treated with leflunomide, mycophenolate, or methotrexate, only 41% had contraception use documented and only 35% had documentation of contraception counseling. This project aimed to increase contraceptive counseling documentation to over 70% for all rheumatologic patients on teratogenic medications within the next nine months.

Methods: Eligibility criteria for counseling included patients with any rheumatologic condition who were maintained on methotrexate, mycophenolate, or leflunomide and were being followed at the UCSF Rheumatology Clinic at the Parnassus location, either through in-person or telehealth visits. The team used the Lean Improvement Methodology to identify the gaps in contraceptive screening and counseling (Figure 1). Most identified gaps led to targeted Interventions which include- Development of a standardized documentation SmartPhrase in the electronic health record (EHR)- Collaboration with the complex contraception clinic withing the OB/GYN department to create patient-facing educational materials- Training of nursing staff to conduct contraceptive counseling- Workflow redesign to include counseling across visit types (telemedicine and in-person)- Monthly audits tracked counseling documentation rates among patients prescribed the three targeted teratogenic medications.

Results: Over the course of the project, we reviewed our findings every six weeks by monitoring the in-process metric, which was the percentage of eligible patients missed during each intervention cycle. This was measured to evaluate progress and determine if further changes were necessary. In the first two months, despite implementing targeted interventions, approximately 60% of eligible patients were still missed for contraceptive counseling. This gap was primarily due to challenges in capturing patients seen via telehealth, a limitation of the existing clinic workflow. After identifying this issue, we revised the workflow, enabling nurses with training in contraceptive counseling to proactively identify our target patient sample whether they were receiving care via telehealth and in-person. These changes significantly improved outcomes: documented contraceptive counseling rates rose from 35% (N&#3f109) at baseline to 82% (N&#3f331) (Figure 2), and the proportion of missed eligible patients dropped from 64% in November 2024 to 1.82% in April 2024 (Figure 3). Whenever counseling occurred, contraceptive use was documented in 100% of cases, indicating whether or not the patient was using contraception.

Conclusion: A multidisciplinary, systems-based approach led to a substantial improvement in contraceptive counseling rates for patients on teratogenic medications.

Supporting image 1Figure 1. Fishbone Diagram Identifying Barriers to Contraceptive Counseling for Patients on Teratogenic Medications. This diagram outlines the root causes contributing to missed contraceptive counseling opportunities.

Supporting image 2Figure 2. A line graph showing the percentage of eligible patients with documented counseling, increasing from 35% at baseline to 82% after the intervention period.

Supporting image 3Figure 3. In-process metric showing Reduction in Missed Eligible Patients for Contraceptive Counseling. This is a line graph displaying the decline in missed counseling opportunities, from 64% in November 2024 to 1.82% in April 2025, following workflow revisions and nurse-led interventions.


Disclosures: A. Fadairo-Azinge: None; j. Romulo: None; D. Flores: None; j. Giron: None; J. Ng: None; S. Patterson: None; J. Yazdany: AstraZeneca, 2, Aurinia, 5, Gilead, 5; A. Gross: None.

To cite this abstract in AMA style:

Fadairo-Azinge A, Romulo j, Flores D, Giron j, Ng J, Patterson S, Yazdany J, Gross A. Enhancing Patient Safety: Improving Contraceptive Counseling for Patients on Teratogenic Medications in the Rheumatology Clinic [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/enhancing-patient-safety-improving-contraceptive-counseling-for-patients-on-teratogenic-medications-in-the-rheumatology-clinic/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/enhancing-patient-safety-improving-contraceptive-counseling-for-patients-on-teratogenic-medications-in-the-rheumatology-clinic/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology